Proxy Votes Now

Home › Funds › Victory Capital › Victory Science & Technology Fund

Victory Science & Technology Fund (USSCX) proxy voting record 2025-2026

Fund family: Victory Capital · Filed by VICTORY PORTFOLIOS III (CIK 908695) · SEC series S000012911

Share classes and tickers: USSCX (C000034880), USTCX (C000220624)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,563 with, 92 against, 1 abstentions (not counted as with management); 2 items carried no recommendation; 10 split votes are in neither count. Shareholder proposals: 28 FOR, 57 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Victory Capital as a whole

The same two figures as Victory Capital’s manager page (160,780 ballot items across 92 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsVictory CapitalItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)90.8%1,47393.2%139,221
Backed environmental and social shareholder proposals at US companies11.5%524.4%2,755

Where this fund voted differently from most Victory Capital funds

Each ballot item this fund voted is set against the votes of the other Victory Capital funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Victory Capital funds on 28 items (3.1% of the 902 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Victory Capital fundsMgmtResult
Bristol-Myers Squibb Company2026-05-05Shareholder Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent DirectorForAGAINST — 27 of 27 Victory Capital fundsAgainstNot approved, 27.6% support
Bristol-Myers Squibb Company2026-05-05Election of Directors: Derica W. RiceAgainstFOR — 27 of 27 Victory Capital fundsAgainstElected, 97.2% support
NetApp, Inc.2025-09-10To approve an amendment to NetApp's 2021 Equity Incentive Plan.ForAGAINST — 26 of 26 Victory Capital fundsForApproved, 68.0% support
CVS Health Corporation2026-05-14Shareholder Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent.AgainstFOR — 22 of 22 Victory Capital fundsFor—
Oracle Corporation2025-11-18Advisory Vote to Approve the Compensation of our Named Executive OfficersForAGAINST — 18 of 18 Victory Capital fundsForPassed (calculated), 81.9% support
Advanced Micro Devices, Inc.2026-05-13Election of Directors: Abhi Y. TalwalkarAgainstFOR — 15 of 15 Victory Capital fundsAgainstPassed (calculated), 91.7% support
Autodesk, Inc.2026-06-17Election of Directors: John T. CahillAgainstFOR — 13 of 13 Victory Capital fundsAgainstPassed (calculated), 94.7% support
Autodesk, Inc.2026-06-17Approval of an amendment of our Amended and Restated Certificate of Incorporation to provide for officer exculpation as permitted by Delaware law.AgainstFOR — 12 of 12 Victory Capital fundsAgainstPassed (calculated), 81.5% support
Datadog, Inc.2026-06-15To elect four Class I directors, each to hold office until our Annual Meeting of Stockholders in 2029: Dev IttycheriaForWITHHOLD — 10 of 10 Victory Capital fundsForElected, 88.8% support
Datadog, Inc.2026-06-15To elect four Class I directors, each to hold office until our Annual Meeting of Stockholders in 2029: Shardul ShahForWITHHOLD — 10 of 10 Victory Capital fundsForElected, 83.8% support
United Therapeutics Corporation2026-06-26Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.ForAGAINST — 10 of 10 Victory Capital fundsForPassed (calculated), 72.0% support
Incyte Corporation2026-06-08Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Julian C. BakerAgainstFOR — 10 of 10 Victory Capital fundsAgainstElected, 80.9% support
Zscaler, Inc.2026-01-12To approve on a non-binding, advisory basis, the compensation of our named executive officers.AgainstFOR — 9 of 9 Victory Capital fundsAgainstApproved, 93.2% support
CrowdStrike Holdings, Inc.2026-06-17To approve an amendment and restatement of CrowdStrike's amended and restated certificate of incorporation to limit officer liability as permitted by Delaware law.AgainstFOR — 8 of 8 Victory Capital fundsAgainstApproved, 85.4% support
Shopify Inc.2026-06-16Election of Director: Fidji SimoAgainstFOR — 8 of 8 Victory Capital fundsAgainstElected, 96.7% support
Danaher Corporation2026-05-05To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: A. Shane SandersForAGAINST — 6 of 6 Victory Capital fundsForElected, 73.8% support
Danaher Corporation2026-05-05To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: Teri L. ListForAGAINST — 6 of 6 Victory Capital fundsForElected, 77.7% support
Regeneron Pharmaceuticals, Inc.2026-06-12Election of Directors: Christine A. PoonForAGAINST — 9 of 10 Victory Capital fundsForElected, 76.8% support
Regeneron Pharmaceuticals, Inc.2026-06-12Election of Directors: Craig B. Thompson, M.D.ForAGAINST — 9 of 10 Victory Capital fundsForElected, 79.3% support
Regeneron Pharmaceuticals, Inc.2026-06-12Election of Directors: Joseph L. Goldstein, M.D.ForAGAINST — 9 of 10 Victory Capital fundsForElected, 70.1% support
Boston Scientific Corporation2026-04-30Proposal to elect ten Directors: David C. HabigerAgainstFOR — 5 of 5 Victory Capital fundsAgainstElected, 85.9% support
MKS Inc.2026-05-11The approval, on an advisory basis, of a Company proposal to reduce the threshold percentage of shareholders required to call a special meeting of shareholders from 40% to 25%.AbstainFOR — 4 of 4 Victory Capital fundsAgainstPassed (calculated), 98.5% support
Scholar Rock Holding Corporation2026-06-04To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.ForAGAINST — 4 of 4 Victory Capital fundsForApproved, 61.7% support
Stoke Therapeutics, Inc2026-06-03To approve, on an advisory basis, the compensation of the Company's named executive officers.ForAGAINST — 4 of 4 Victory Capital fundsForPassed (calculated), 72.9% support
Bio-Techne Corporation2025-10-30Approve, on an advisory basis, the compensation of our executive officers.ForAGAINST — 3 of 3 Victory Capital fundsForApproved, 72.1% support
Show all 28
Items 26 to 28.
CompanyMeetingItemThis fundMost Victory Capital fundsMgmtResult
Madrigal Pharmaceuticals, Inc.2026-06-17Re-election of Class I directors: Julian BakerWithholdFOR — 3 of 3 Victory Capital fundsAgainstElected, 88.6% support
Dianthus Therapeutics, Inc.2026-05-21To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorgeForWITHHOLD — 3 of 3 Victory Capital fundsForPassed (calculated), 80.6% support
Mineralys Therapeutics, Inc.2026-05-212 wordings Election of Class III directors for a three-year term to expire at the 2029 annual meeting of stockholders: Srinivas Akkaraju, M.D., Ph.D.ForWITHHOLD — 3 of 3 Victory Capital fundsForPassed (calculated), 60.6% support

Download all 28 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 82.4% of this fund’s 1,656 such votes could be given a sector; the other 291 (17.6%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care612193.1%
Technology5425610.3%
Consumer Discretionary831416.9%
Industrials7822.6%
Consumer Staples1715.9%
Finance1100.0%
Miscellaneous1100.0%
Telecommunications700.0%
Utilities400.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections1,0375
Audit-related1680
Say-on-Pay1441
Corporate Governance9712
Compensation874
Capital Structure633
Other Social Issues2926
Shareholder Rights and Defenses2815
Human Rights or Human Capital/workforce1111
Environment or Climate88

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Meta Platforms, Inc.May 27, 2026$96M3711
NVIDIA CorporationJune 24, 2026$85M264
Microsoft CorporationDecember 5, 2025$79M248
Amazon.com, Inc.May 20, 2026$47M174
Guardant Health, Inc.June 17, 2026$32M50
MACOM Technology Solutions Holdings, Inc.March 5, 2026$31M100
Coherent Corp.November 13, 2025$31M120
AppLovin CorporationJune 3, 2026$31M193

Notable votes against management

MeetingCompanyProposalFundMgmt
May 27, 2026Meta Platforms, Inc.A shareholder proposal regarding report on Al data usage oversight. Shareholder proposalAgainstFor
May 27, 2026Meta Platforms, Inc.A shareholder proposal regarding annual vote regarding executive pay. Shareholder proposalForAgainst
June 24, 2026NVIDIA CorporationApproval of a non-binding stockholder proposal requesting the replacement of supermajority voting provisions in our charter and bylaws with a simple majority voting standard. Shareholder proposalForAgainst
June 24, 2026NVIDIA CorporationApproval of a non-binding stockholder proposal requesting a report on faith-based community resource groups. Shareholder proposalAgainstFor
December 5, 2025Microsoft CorporationEuropean Security Program Censorship Risk Audit Shareholder proposalAgainstFor
December 5, 2025Microsoft CorporationReport on Risks of Censorship in Generative Artificial Intelligence Shareholder proposalAgainstFor
May 20, 2026Amazon.com, Inc.Shareholder Proposal Requesting A Report On Charitable Partnerships Shareholder proposalAgainstFor
May 20, 2026Amazon.com, Inc.Shareholder Proposal Requesting Additional Reporting On Impact Of Data Centers On Climate Commitments Shareholder proposalAgainstFor
June 3, 2026AppLovin CorporationElection of Directors: Adam ForoughiWithholdFor
June 3, 2026AppLovin CorporationElection of Directors: Eduardo VivasWithholdFor
January 27, 2026Visa Inc.Shareholder proposal on report on online sexual exploitation. Shareholder proposalAgainstFor
January 27, 2026Visa Inc.Shareholder proposal on inclusion ROI audit. Shareholder proposalAgainstFor

Search this fund’s votes by company

1,681 ballot items at 166 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Victory Science & Technology Fund (USSCX) voted at 166 shareholder meetings of 159 companies, on 1,681 ballot items in all. Where management made a recommendation, the fund followed it on 94.4% of the items and voted against it 92 times. Its most frequent area of disagreement was other social issues (26 of its votes against management). It voted FOR 32.9% of the 85 shareholder proposals on which it cast a FOR or AGAINST vote. It voted FOR the board's own proposals less often than Victory Capital's funds as a whole (90.8% against 93.2%). It voted differently from most Victory Capital funds on 28 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Victory Capital’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.